Atopic Dermatitis

Kim Kjoller, MD: BLA for Tralokinumab and the Next Steps

July 31, 2020

Video

The FDA will be working over the next few months to ensure tralokinumab is efficient for atopic dermatitis.

Kim Kjoller, MD: Comparing Tralokinumab to Other Agents for Atopic Dermatitis

July 31, 2020

Video

An expert explains differences between tralokinumab and other popular agents for atopic dermatitis.

Upadacitinib Plus Topical Corticosteroids Effective for Atopic Dermatitis

July 28, 2020

Article

The data from the phase 3 AD Up trial add to existing knowledge of the efficacy and safety of upadacitinib for patients with atopic dermatitis.

Kim Kjoller, MD: Results of Tralokinumab Trials

July 24, 2020

Video

Kim Kjøller, MD, breaks down the findings from ECZTRA1, 2, and 3.

Kim Kjoller, MD: Tralokinumab for Atopic Dermatitis

July 24, 2020

Video

Kim Kjøller, MD, discusses how tralokinumab can be used for the treatment of atopic dermatitis.

Upadacitinib Demonstrates Safety and Efficacy for Atopic Dermatitis

July 21, 2020

Article

Upadacitinib 15 mg and 30 mg outperformed placebo in Measure Up 2, the second part of a phase 3 study on the monotherapy.

Nemolizumab, Topical Agents Reduce Pruritus Related to Atopic Dermatitis

July 09, 2020

Article

Subcutaneous injections of nemolizumab in addition to topical agents result in a greater reduction in pruritus than placebo plus topical agents.

FDA Approves Pre-Filled Dupilumab Pen

June 19, 2020

Article

The FDA is allowing the pen to be used for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP) patients at least 12 years old.

FDA Approves Dupilumab for Pediatric Eczema

May 26, 2020

Article

The newest indication for the add-on biologic grants it use in children aged 6-11 years old with moderate to severe, uncontrolled atopic dermatitis.

Dupilumab, Cyclosporine Better Competitors for Atopic Dermatitis Clearance

May 03, 2020

Article

A systematic review and meta-analysis show the systemic therapies, as well as a couple investigational biologics, may be superior.

x